Highlights
- Pumecitinib 3% gel BID achieved an 83.6% reduction in EASI scores at week 8, significantly outperforming placebo.
- Twice-daily (BID) administration demonstrated superior efficacy compared to once-daily (QD) dosing.
- Systemic exposure remained exceptionally low (38-104 pg/mL), suggesting a reduced risk of systemic JAK-inhibitor-related adverse events.
- The safety profile was comparable to placebo, with high local tolerability observed throughout the 8-week study period.
Introduction: The Therapeutic Challenge of Atopic Dermatitis
